Overview
Title
To amend the Internal Revenue Code of 1986 to establish a refundable credit for expenses incurred for in vitro fertilization.
ELI5 AI
H. R. 9479 is a plan to give money back as a tax credit to people in the USA who spend on special baby-making treatments called in vitro fertilization (IVF). If it becomes law, people could get up to $30,000 refunded for these expenses, making it easier to afford having a baby this way.
Summary AI
H. R. 9479 seeks to amend the Internal Revenue Code of 1986 to create a new refundable tax credit for individuals who incur expenses related to in vitro fertilization. The credit would allow individuals to receive a tax break for qualified medical expenses, up to $30,000, not previously claimed in prior years. It also specifies that any expenses covered by this credit cannot be used for other tax deductions or credits. The bill would be effective for expenses incurred after its enactment.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
Summary of the Bill
The proposed legislation, H.R. 9479, aims to amend the Internal Revenue Code of 1986 by introducing a refundable tax credit specifically designated for expenses related to in vitro fertilization (IVF). This bill allows individuals to claim a tax credit for qualified IVF expenses, subject to an annual limit of $30,000. The credit amount is reduced by any prior credits claimed in previous years, prohibiting double claims for the same expenses with other tax benefits. This effort seeks to alleviate some of the financial burdens associated with IVF treatments by providing tax relief to eligible individuals.
Significant Issues
A number of issues arise from the provisions laid out in the bill, which may affect its implementation and overall effectiveness:
Potential for Misuse: The bill lacks explicit provisions to prevent misuse or abuse of the credit system, such as fraudulent claims. This could lead to increased costs for the government without ensuring that the intended beneficiaries receive appropriate support.
Absence of Income Limits: The proposed credit does not include income thresholds or criteria for eligibility, potentially allowing high-income individuals who might not need financial assistance to benefit. This could result in an inequitable distribution of financial support among those who seek IVF treatment.
Complexity and Ambiguity: The legal language used in the bill, particularly in defining "qualified in vitro fertilization expenses," may be challenging for taxpayers to comprehend. Without clear verification guidelines for these expenses, there may be confusion about eligibility and proper utilization of the credit.
Long-term Fiscal Impact: The absence of an overall cap on the total credit available over multiple years could lead to unforeseen fiscal implications if a large number of taxpayers apply for this credit annually. This lack of financial control could strain government resources in the long term.
Impact on the Public and Stakeholders
Broadly speaking, the bill could significantly affect individuals who are undergoing IVF treatments, offering potential financial relief through tax credits. For many families, this legislation could mean improved access to reproductive health services, provided they are informed of and eligible for the credit.
However, the potential benefits might largely favor those who can afford the initial costs of IVF, as the relevant expenses need to be incurred before claiming the credit. Consequently, individuals and families with lower incomes who might struggle to pay upfront may not fully realize the benefits of this tax relief.
For higher-income individuals, the bill offers a financial advantage that might not be crucial for their decision to pursue IVF. This raises questions of fairness and whether such financial support should prioritize those with greater financial need.
Tax professionals and advisors may see increased demand for their services as complexity in understanding and applying for this credit could drive taxpayers to seek expert assistance.
Overall, while the bill is designed to support families seeking IVF treatments, scrutiny of its financial implications, eligibility criteria, and operational clarity is essential to ensuring that its benefits are equitably distributed and sustainable over time.
Financial Assessment
The proposed bill, H. R. 9479, seeks to amend the Internal Revenue Code to introduce a new refundable tax credit aimed at alleviating the financial burden of in vitro fertilization (IVF) expenses. This financial allocation would allow individuals to claim a tax credit of up to $30,000 for specified qualified medical expenses related to IVF, providing potential relief to those facing substantial costs associated with fertility treatments. Below is an analysis of how these financial elements are presented in the bill and the related concerns.
Financial Summary
The primary financial component of this bill is the creation of a refundable tax credit, which allows taxpayers to reduce their tax liability against qualified IVF expenses. The credit is structured to offset up to $30,000 of these expenses in a given tax year. Notably, this credit is refundable, meaning that if the credit exceeds the individual’s tax liability, the taxpayer would receive the difference as a refund. The credit is designed to be applied to any medical care costs as they relate to IVF, as defined under section 213(d) of the Internal Revenue Code.
The bill specifies that these expenses must not have been claimed as deductions or credits previously, ensuring that taxpayers cannot double-dip into tax benefits for the same expense. This stipulation aims to maintain fairness, yet it also implies a level of complexity as individuals must keep comprehensive records of their past medical expense claims.
Issues and Implications
Potential for Misuse or Fraud: One concern is that the introduction of such a tax credit poses a risk of misuse or fraudulent claims, as mentioned in the issues. Without robust mechanisms to verify the authenticity and eligibility of claims, individuals could potentially exploit the credit system, leading to unwarranted financial burdens on the government.
Equity Concerns: The absence of income restrictions in the bill means that individuals at higher income levels, who may already have the means to afford IVF treatments, could benefit from the tax credit. This raises an equity concern, as the financial benefits might not reach those who need it the most, potentially skewing the support toward those with greater financial capacity.
Fairness and Accessibility: Another critical point raised is the fairness of the credit application. Individuals who cannot pay for IVF treatments upfront may not be able to benefit from this credit as they would still need to cover the initial costs before claiming the credit in their taxes. This situation potentially favors those who are already financially resilient, thereby creating an unfair advantage.
Lack of Specificity in Definitions: The term "qualified in vitro fertilization expenses" links back to medical care definitions, which could be interpreted variably without clear guidelines provided in this bill. This lack of specification could lead to confusion among both taxpayers and tax authorities, complicating the credit claiming process.
Risk of High Costs Over Time: The absence of a total lifetime cap on the amount of credit a taxpayer can claim over multiple years could lead to substantial long-term costs if many taxpayers frequently claim the maximum credit limit annually. This presents a significant fiscal concern for government expenditure, pointing to a need for balanced financial management and oversight.
The financial provisions in the bill reflect a well-intended effort to aid individuals and families navigating the high costs of fertility treatments, but they also highlight several areas of concern that may require further refinement to ensure the credit is applied fairly, verifiably, and sustainably.
Issues
The bill introduces a new tax credit specifically for in vitro fertilization expenses, but might lack provisions to prevent potential misuse or abuse of this credit system, as outlined in Section 1. This could lead to fraudulent claims and increased financial burden on the government.
The absence of income limits or criteria in Section 36C may result in the tax credit being available to higher-income individuals who may not need financial assistance for in vitro fertilization expenses, creating inequity in financial support distribution.
Section 1 raises concerns about fairness as individuals who cannot afford in vitro fertilization expenses upfront might not benefit equally from the tax credit, leading to a potential unfair advantage for individuals with higher incomes.
There is a lack of specificity in Section 1 about how 'qualified in vitro fertilization expenses' are verified, which could lead to ambiguity in its application and create confusion for taxpayers and tax authorities.
The language in Sections 1 and 36C, particularly subsection (a), is complex and might be difficult for taxpayers to understand, potentially complicating the eligibility and process of claiming the tax credit.
Section 36C uses the term 'qualified in vitro fertilization expenses,' linked to 'medical care' as defined in Section 213(d), but the lack of full context may lead to varying interpretations of eligible expenses.
The absence of a total cap on the credit amount available over multiple tax years in Sections 1 and 36C could result in unforeseen high costs over the long term if many taxpayers claim this credit annually, posing a significant fiscal concern.
Section 1 may lead to increased complexity in tax returns, as taxpayers must track prior credits claimed under this section, which may necessitate professional tax assistance.
There is no specified cap in Section 1 on the potential total expenditure or cost to the government over time, leading to concern about long-term fiscal implications.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. In vitro fertilization credit Read Opens in new tab
Summary AI
The section introduces a tax credit for individuals' in vitro fertilization expenses, allowing them to claim up to $30,000 in qualified medical care costs related to the procedure. The credit is reduced by the amount received in previous years, and it cannot be combined with other deductions or credits for the same expenses.
Money References
- “(a) Allowance of credit.—In the case of an individual, there shall be allowed as a credit against the tax imposed by this subtitle an amount equal to so much of the qualified in vitro fertilization expenses of the individual for the taxable year as do not exceed the excess (if any) of— “(1) $30,000, over “(2) the aggregate amount allowed as a credit to the taxpayer under this section for all prior taxable years. “
36C. In vitro fertilization credit Read Opens in new tab
Summary AI
The section outlines a tax credit for individuals who have qualified in vitro fertilization expenses. It allows them to claim a credit up to $30,000 for these expenses, reduced by any credit received in previous years, and ensures that they cannot claim a double benefit for the same expenses.
Money References
- (a) Allowance of credit.—In the case of an individual, there shall be allowed as a credit against the tax imposed by this subtitle an amount equal to so much of the qualified in vitro fertilization expenses of the individual for the taxable year as do not exceed the excess (if any) of— (1) $30,000, over (2) the aggregate amount allowed as a credit to the taxpayer under this section for all prior taxable years. (b) Qualified in vitro fertilization expenses.—For purposes of this section, the term “qualified in vitro fertilization expenses” means amounts paid or incurred for medical care (as defined in section 213(d)) relating to in vitro fertilization for the taxpayer (or the taxpayer’s spouse, in the case of a joint return).